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January 2013288 Abstractsrupture and aneurysm diameter relative to body size for men and women
with the goal of testing a novel method of rupture risk stratification that is
more appropriate for women.
Methods:We reviewed all patients in the Vascular Surgery Group of
New England database who underwent endovascular or open AAA
repair. We evaluated height, weight, body mass index (BMI), and body
surface area (BSA) as well as each of these values indexed to the aortic
diameter (eg, BSA index  aneurysm diameter (cm)/BSA [m2]). Along
with other relevant clinical variables, we constructed multivariable-ad-
justed logistic regression models using forward selection to determine
predictors of rupture repair vs elective repair. Models for men and women
were developed separately, and different models were compared using
the area under the curve (AUC).
Results:We identified 4045 patients who underwent AAA repair (11%
ruptured, 53% EVAR, 78% men). Women had significantly smaller diameter
aneurysms, lower BSA, and higher BSA indices than men (Table). For men,
the primary determinant of rupture was aneurysm diameter (AUC, 0.82):
55 mm (referent); 55-64 mm (OR, 0.9; 95% CI, 0.5-1.7; P  .771);
65-74 mm (OR, 3.9; 95% CI, 1.9-1.0; P .001); and75 mm (OR, 11.3;
95% CI, 4.9-25.8; P .001). In contrast, BSA index was most predictive of
rupture for women (AUC, 0.81), with higher odds of rupture at higher BSA
indices: 25 (OR, 3.9; 95% CI, 0.5-28.2; P  .175); 25-29 (OR, 3.3; 95%
CI, 0.8-14.5; P  .111); 30-34 (referent); 35-39 (OR, 6.4; 95% CI,
1.7-24.1; P  .006); and 40 (OR, 9.5; 95% CI, 2.3-39.4; P  .002). For
women, aneurysm diameter alone was not a significant predictor of rupture
after adjusting for BSA index.
Conclusions: Aneurysm diameter indexed to body size is the most
important determinant of rupture for women, whereas aneurysm diameter
alone is most predictive of rupture for men. Women with the largest
diameter aneurysms and the smallest body sizes are at the greatest risk of
rupture.
Table. Demographics and multivariable predictors of ruptured repair
Variables
Men
(n  3138)
Women
(n  907) P
Demographics
Age, mean (SD) years 71.9 (8.7) 74.3 (7.7) .001
Aneurysm diameter, mm .001
20-54, No. (%) 1032 (32.9) 368 (40.6)
55-64, No. (%) 1170 (37.3) 350 (38.6)
65-74, No. (%) 452 (14.4) 111 (12.2)
75, No. (%) 483 (15.4) 78 (8.6)
BSA, m2a .001
1.8, No. (%) 405 (12.9) 551 (60.7)
1.8-1.9, No. (%) 1073 (34.2) 258 (28.5)
2.0, No. (%) 1660 (52.9) 98 (10.8)
BSA index, cm/m2b .001
25, No. (%) 668 (21.3) 77 (8.5)
25-29, No. (%) 1136 (36.2) 231 (25.5)
30-34, No. (%) 678 (21.6) 297 (32.7)
35-39, No. (%) 342 (10.9) 171 (18.8)
40, No. (%) 314 (10.0) 132 (14.5)
Predictors of ruptured
repair OR (95% CI)c P OR (95% CI)d P
Aneurysm diameter, mm
20-54, % 1.0 1.0
55-64, % 0.9 (0.5-1.7) .8 1.1 (0.3-3.7) .85
65-74, % 3.9 (1.9-8.0) .01 3.3 (0.8-12.7) .09
75, % 11.3 (4.9-25.8) .01 3.2 (0.7-14.5) .13
BSA Index, cm/m2b
25, % 0.6 (0.3-1.4) .23 3.9 (0.5-28.2) .18
25-29, % 0.8 (0.5-1.5) .53 3.3 (0.8-14.5) .11
30-34, % 1.0 1.0
35-39, % 0.8 (0.5-1.4) .52 6.4 (1.7-24.1) .01
40, % 1.4 (0.8-2.6) .2 9.5 (2.3-39.4) .01
aBSA  BSA (m2)  0.20247  Height (m)0.725 Weight (kg)0.425.
bBSA index  aneurysm diameter (cm)/BSA (m2).
cArea under the curve  0.82.
dArea under the curve  0.81.
A 20-Year Experience With Endovascular Repair of Abdominal Aortic
Aneurysms: A Record of the Development and Evolution of Tech-
niques, Devices, and Strategies
Rami O. Tadros, MD, Peter L. Faries, MD, Hannah L. Lowe, MD, Rachel
Schrier, MD, Robert A. Lookstein, MD, Sung yup P. Kim, MD, Jamie Kim,
MD, Ageliki G. Vouyouka, MD, Sharif H. Ellozy, MD, Michael L. Marin,
MD. The Mount Sinai School of Medicine, New York, NY
e
FObjectives: Endovascular repair of abdominal aortic aneurysms (EVAR)
as become the first-line treatment of abdominal aortic aneurysms (AAA)
orldwide. Since the first successful EVAR in North America, the authors have
aintained a continuous, prospective database recording the details of each
rocedure.
Methods: Between 1992 and 2012, 1268 patients (mean age, 75 years;
5% men) underwent EVAR for repair of AAA. Fifteen different types of stent
rafts were used (Table). Eighty-one percent of patients exhibited high-risk
haracteristics that would preclude participation in Food andDrug Administra-
ion-mandated, industry sponsored-IDE pivotal trials. Ninety-three percent of
atients had at least one severe comorbid medical condition, with an average of
.2 conditions per patient. During EVAR, 38% had concomitant treatment
f associated common iliac artery aneurysms.Mean follow-up was 38.2 months.
Results: Major perioperative complications occurred in 7.5%, with a
erioperative mortality rate of 2.5%. Aneurysm size remained stable or
ecreased (5 mm) in 86.5% of patients and increased (5 mm) in 13.5%;
edian time to aneurysm expansion was 8.2 years. During follow-up, type I
ndoleak occurred in 2.1% of patients and type III in 0.2%. Reintervention
as required in 21% of patients.Mean time to reintervention was 26months.
reedom from aneurysm-related mortality was 91.1% at 12 years. Median
urvival for all-cause mortality was 5.6 years.
Conclusions: Progressive advances in EVAR allow safe, effective, and
urable repair of AAA, extending the instructions for use parameters of
ommercially available devices.
able 1. Operative data
Mean SD
nesthesia time (hours) 5.05  1.51
urgery time (hours) 3.70  1.47
stimated blood loss (mL) 367.8  515.3
ransfusion volume (mL) 645.3  647.4
ength of hospitalization (days) 2.75  5.96
nitial aneurysm size (cm) 5.9  1.2
neurysm size at latest F/U (cm) 5.5  1.6
No. of patients %
re-operative adjunctive procedure(s) 438 34.6%
atients receiving transfusion 181 14.3%
eneral anesthesia 75 5.9%
pinal or epidural anesthesia 1085 85.8%
ube graft 59 4.7%
ifurcated graft 992 78.2%
orto-uni-iliac graft 207 16.3%
hysician-made EVSGs 109 8.6%
ndustry-made EVSGs 1159 91.4%
ischarge on postoperative day 0 or 1 802 63.4%
ajor perioperative complications 95 7.5%
erioperative mortality 32 2.5%
he Incidence of Contralateral Iliac Venous Thrombosis After Stent-
ng Across the Iliocaval Confluence in Patients With Acute or Chronic
enous Outflow Obstruction
zabia A. Caliste, MD, Amanda L. Clark, BS, John P. Cullen, PhD, Craig
arins, MD, Ankur Chandra, MD, Jennifer Ellis, MD, Jason Kim, MD,
ichael Singh, MD, David L. Gillespie, MD. University of Rochester
edical Center, Division of Vascular Surgery, Rochester, NY
Objectives: Percutaneous transluminal angioplasty and stenting of the
liac veins is becoming a more common method of treating patients with
ymptomatic lower extremity venous outflow obstruction. Several questions
bout the conformation of these stents remain to be answered. One, in
articular, is whether these venous stents should extend into the vena cava or
top short of this in fear of causing further harm to the patient’s contralateral
eg.
Methods: We retrospectively reviewed prospectively collected data
rom 2008 to 2012 in patients with symptomatic iliocaval venous thrombo-
is who underwent percutaneous angioplasty and stenting. Data were col-
ected using the AVF venous stent database variables. Most patients were
aintained on full anticoagulation using warfarin (international normalized
atio 2-3) or low-molecular-weight heparin (weight-based daily or b.i.d.
osing). Patients with first time deep venous thrombosis were anticoagu-
ated for 6 months on average, and those with repeat deep venous throm-
osis were maintained on lifelong anticoagulation. Intraoperative anticoag-
lation was performed using intravenous heparin. Contralateral thrombosis
nd patency rates were recorded.
Results: A total of 183 iliocaval stents were placed in 66 patients
median age, 43; range 15-80 years), of which 63 patients experienced
hrombosis causing the venous outflow obstruction. Thirty patients experi-
nced acute venous thrombosis, 25 chronic, and nine acute on chronic.
orty-eight of 66 patients (72.7%) had patent stents noted on duplex
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Volume 57, Number 1 Abstracts 289ultrasound imaging at 1 year, 10 patients have no follow-up data (three of
whom surgery was recently completed, seven of which were lost to follow-
up), and eight patients experienced thrombosis. Stents extended into the
inferior vena cava crossing the normal contralateral side in 45 of 66 patients
(68%). Seven of these patients (15%) suffered new thrombosis of the
nonstented contralateral side. Three of these seven patients were totally
noncompliant with their postoperative anticoagulation; thus, 8% of compli-
ant patients had new contralateral thrombosis after stenting across a normal
contralateral common iliac vein and into the vena caval wall.
Conclusions: To date, there is no consensus whether to stent across
the thrombosed common iliac vein into the cava or completely across and
into the vena cava. From these data it appears that stenting across the
iliocaval confluence can result in a small percentage of contralateral throm-
bosis despite chronic therapeutic anticoagulation. This data will help us
move forward in the development of new technologies and in the treatment
of these patients.
Surgical Reconstruction of the Cephalic Arch for the Management of
Dysfunctional Brachiocephalic Arteriovenous Fistulas
Javier E. Anaya-Ayala, MD, Nader Zamani, BS, Nyla Ismail, PhD, Tony Lu,
MD, Cassidy Duran, MD, Hosam F. El-Sayed, MD, Mark G. Davies, MD,
PhD, MBA, Eric K. Peden, MD. Methodist DeBakey Heart & Vascular
Center, Houston, Tex
Objectives:Development of recalcitrant stenotic lesions of the cephalic
arch is a common failure mode of brachiocephalic arteriovenous fistulas.
Endovascular treatment is the first line of therapy for cephalic arch stenosis.
Suboptimal outcomes have led to exploration of surgical alternatives. We
evaluated our initial experience with a cephalic arch reconstruction to salvage
malfunctioning brachiocephalic arteriovenous fistulas (AVFs).
Methods: We retrospectively reviewed all patients requiring surgical
revision of compromised brachiocephalic AVFs due to cephalic arch stenosis.
Percutaneous interventions had failed in all patients, and they underwent
cephalic arch reconstruction (CAR) for salvage. Indications, clinical consid-
erations, and surgical technique were studied; initial patency, complications
and reinterventions were reviewed.
Results: From April 2011 to July 2012, 15 patients (54% women, mean
age 55 22 years) underwent CAR. Stenotic lesions of the cephalic arch at the
confluence with the axillary vein were confirmed by contrast venography. The
average number of percutaneous interventions prior to the decision toCARwas
three (range, 2-7).The time fromaccess creation to cephalic arch reconstruction
was 33 months. Surgical approach involved revisions of the cephalic arch to
redirect the flow as a direct reconnection to the axillary or as a turndown
procedure to the brachial vein in the axilla. Technical success was 100%: all
patients were able to use successfully their access for dialysis after the procedure.
Two patients (13%) required angioplasty of the CAR due to restenosis, another
patient required evacuation of hematoma in postoperative day 14. At a mean of
12 months of follow-up, all AVFs remain functional.
Conclusions: The initial experience with cephalic arch reconstruction
demonstrates that is an effective surgical option to salvage brachiocephalic
AVFs with excellent short-term and functional results (Fig).
Transarterial Treatment of Congenital Renal Arteriovenous Fistulas
Naiem Nassiri, MD, Hirra Ali, MD, Alfio Carroccio, MD, Robert J. Rosen,
MD. Lenox Hill Heart & Vascular Institute of New York, New York, NY
Objectives: Congenital renal arteriovenous fistulas (CRAVFs) repre-
sent a distinct and often misdiagnosed clinical entity with characteristic
hemodynamic and angiographic features. Treatment is warranted given
potential for growth with renal and hemodynamic compromise. We report
our experience with a series of treated symptomatic CRAVFs.
Fig.Methods: During a 10-year period, patients treated for symptomatic
CRAVFs (no history of predisposing renal pathology, instrumentation,
a
eeoplasm, or trauma) were retrospectively investigated for clinical presenta-
ion, radiographic features, treatment outcomes, and complications. A tech-
ically successful treatment included successful delivery of an embolic agent
ith complete obliteration of the fistula. Clinical success included resolution
f symptoms and freedom from recurrence and reintervention. Renal paren-
hymal loss as demonstrated by postembolization angiography was catego-
ized as 0%, 25%, 25% to 50%, or 50%.
Results: Twenty-five patients (8 women) were referred with a pre-
umptive diagnosis of intraparenchymal renal artery aneurysm. Of these, 10
ad true intrarenal aneurysms, three had angiomyolipomas, and 12 had
RAVFs (mean age, 54 years; range 29-71 years). Presenting symptoms
ncluded gross hematuria (n  8), refractory hypertension (diastolic blood
ressure 90 mm Hg despite 3 medications; n  6), flank pain (n  8),
igh-output state (featuring tachycardia and jugular venous distention; n 
), and flank bruit (n  1). Defining angiographic features included a
igh-flow arteriovenous fistula fed by a single, enlarged intrarenal branch
hunting into a dilated vein, occasionally featuring a calcified rim (n 4). All
atients underwent transarterial embolization with coils (n  5), coils and
-butylcyanoacrylate (n  3), detachable balloons (n  2), or Amplatzer
lugs (n 2). Technical success was 100%. Hematuria, tachycardia, jugular
enous distention, pain, and bruit resolved in all. Hypertension improved in
our of six patients (required one medication after embolization). Compli-
ations included a transient, self-limited postprocedural flank discomfort in
ine patients. Parenchymal loss was limited to 25% and occurred in five
atients. There were no recurrences or reinterventions at a mean follow-up
f 55 months (range, 5-96 months). There was one death at 8 years’
ollow-up from intercurrent coronary disease in a patient without high-
utput state.
Conclusions: CRAVF is a rare and likely underdiagnosed clinical
ntity. With greater awareness and accurate diagnosis, effective and durable
ransarterial treatment can be safely performed (Fig).
actors Associated With Primary Vein Graft Thrombosis in a Multi-
enter Trial With Mandated Ultrasound Surveillance
awrence B. Oresanya, MD,1 Gregory L. Moneta, MD,2 Michael Belkin,
D,3 Michael S. Conte, MD1. 1University of California San Francisco, San
rancisco, Calif; 2Oregon Health and Science University, Portland, Ore;
Brigham and Women’s Hospital, Boston, Mass
Objectives: The benefits of preventing lower extremity vein bypass
raft (LEVBG) occlusion through duplex ultrasound (DUS) surveillance
nd timely reintervention are established. However, even in the setting of
urveillance, a significant number of LEVBG become occluded as a first
vent. We sought to identify factors that may contribute to these primary
cclusions using a multicenter clinical trial database.
Methods: This was a retrospective analysis of the PREVENT III
ohort of 1404 patients with critical limb ischemia who underwent LEVBG.
articipants were followed up with DUS at regular intervals (1, 3, 6, 9, and
2 months), with reintervention based on prespecified DUS criteria. Pa-
ients who had graft occlusion as the initial graft-related event were identi-
ed, and technical failures (adjudicated) were excluded.Multivariate analysis
as used to identify predictors of primary graft occlusion.
Results: Primary graft occlusion occurred in 200 participants (14%),
Fig.ccounting for 34% of all initial graft-related events. Primary occlusion
vents were distributed throughout the postoperative year. Rates of recur-
